Safety and efficacy of pemetrexed for the treatment of lung adenocarcinoma in patients with various stages of chronic kidney disease

Safety and efficacy of pemetrexed for the treatment of lung adenocarcinoma in patients with various stages of chronic kidney disease

We investigated the safety and efficacy of pemetrexed monotherapy in patients with lung adenocarcinoma and various renal conditions, including chronic kidney disease. We also analyzed whether baseline renal function affected progression-free survival (PFS). We retrospectively analyzed 71 patients wh...

Full description

Bibliographic Details
Main Authors:	Jieun Yang, Ji Eun park, Jaemin Jo, Young Ree Kim, Jee Won Chang, Sang Hoon Han, Chi Wha Han
Format:	Article
Language:	English
Published:	Institute for Medical Science, Jeju National University 2022-04-01
Series:	Journal of Medicine and Life Science
Subjects:	pemetrexed adenocarcinoma of lung the elderly chronic renal insufficiency
Online Access:	http://www.e-jmls.org/upload/pdf/jmls-2022-19-1-14.pdf

Similar Items

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
by: Lin Z, et al.
Published: (2017-11-01)

Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
by: Goyal Pankaj, et al.
Published: (2016-01-01)

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
by: Bo Jia, et al.
Published: (2020-12-01)

Serum Homocysteine and Vitamin B12 as Biomarkers for Haematological Toxicity in Lung Adenocarcinoma Treated With Pemetrexed
by: Chang Zhi, et al.
Published: (2019-06-01)

Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
by: Xin Li, et al.
Published: (2021-05-01)

Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy  in Stage IV Lung Adenocarcinoma
by: Youru LIU, et al.
Published: (2011-09-01)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
by: Yan Wang, et al.
Published: (2018-03-01)

Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling
by: Wei-Jing Gong, et al.
Published: (2022-05-01)

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
by: Long-Hua Guo, et al.
Published: (2020-09-01)

Decitabine Sensitizes the Radioresistant Lung Adenocarcinoma to Pemetrexed Through Upregulation of Folate Receptor Alpha
by: Yuqing Wang, et al.
Published: (2021-05-01)

Effect of PD-L1 expression on the efficacy of pemetrexed-based chemotherapy in patients with advanced lung adenocarcinoma and its mechanism
by: SHI Maolin , BAI Yudi , WANG Chao , LI Siqi , ZHOU Daijun , PENG Jingjing , SUN Feifan , LI Dong , ZHANG Tao
Published: (2021-04-01)

Pemetrexed inhibits the proliferation of lung adenocarcinoma cell line A549
by: PAN Shan, LIN Kengqiang, CHEN Shuxing
Published: (2023-09-01)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
by: Schuette W, et al.
Published: (2017-11-01)

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes
by: Jiun-Long Wang, et al.
Published: (2021-08-01)

Pemetrexed induced pneumonitis
by: Binod Dhakal, et al.
Published: (2011-11-01)

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma
by: Yuan Ke, et al.
Published: (2022-05-01)

Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer
by: Chung-Yu Chen, et al.
Published: (2020-10-01)

Clinical Investigation of Efficacy of Pemetrexed in 32 Patients with Pulmonary Adenocarcinoma after Failure to Chemotherapy and Gefitinib
by: Biao WU, et al.
Published: (2010-08-01)

Effects of EGFT-TKIs on Sequential Pemetrexed  for Advanced Pulmonary Adenocarcinoma
by: Xiangying WANG, et al.
Published: (2012-05-01)

New Polymorphic Forms of Pemetrexed Diacid and Their Use for the Preparation of Pharmaceutically Pure Amorphous and Hemipentahydrate Forms of Pemetrexed Disodium
by: Olga Michalak, et al.
Published: (2015-07-01)

Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report
by: Linda Sakhri, et al.
Published: (2017-09-01)

Synthesis and Physicochemical Characterization of the Impurities of Pemetrexed Disodium, an Anticancer Drug
by: Olga Michalak, et al.
Published: (2015-05-01)

Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature
by: Yassir Sbitti, et al.
Published: (2017-07-01)

Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review
by: Tito Zattera, et al.
Published: (2017-04-01)

Pemetrexed in Previously Treated Non-small Cell Lung Cancer Patients with Poor Performance Status
by: Sun Young JUNG, et al.
Published: (2011-01-01)

A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens
by: Satoshi Tanaka, et al.
Published: (2023-09-01)

Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +)
by: A. M. Lozhkina, et al.
Published: (2018-11-01)

Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung
by: Kim D. H., et al.
Published: (2015-06-01)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
by: Zhou Ling, et al.
Published: (2023-03-01)

Effect of Formulation Factors and Oxygen Levels on the Stability of Aqueous Injectable Solution Containing Pemetrexed
by: Dong Han Won, et al.
Published: (2020-01-01)

Efficacy of Pemetrexed as Second-line Therapy or Beyond in Patients  with Advanced Non-small Cell Lung Cancer
by: Junling LI, et al.
Published: (2012-03-01)

Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines
by: Marika Saar, et al.
Published: (2023-05-01)

Validation of Immunohistochemistry for the Detection of <i>BRAF</i> V600E-Mutated Lung Adenocarcinomas
by: Chien-Hung Gow, et al.
Published: (2019-06-01)

PRL-3 antibody combined with pemetrexed induces apoptosis of human lung adenocarcinoma cell line A549
by: SHENG Xin, LIU Dan, DENG Shu-kai
Published: (2020-05-01)

Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC
by: Wang Xia, et al.
Published: (2013-01-01)

Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
by: Ying He, et al.
Published: (2022-05-01)

Clinical Investigation of Efficacy of Third-line and Beyond Pemetrexed Treatment in Advanced Non-squamous Non-small Cell Lung Cancer
by: Fei YU, et al.
Published: (2012-02-01)

Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases
by: Xiaoyan Si, et al.
Published: (2020-08-01)

A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy  for Advanced Non-squamous Non-small Cell Lung Cancer
by: Hongyu DAI, et al.
Published: (2013-08-01)

Blood pressure control in patients with chronic kidney disease
by: Jee Young Lee, et al.
Published: (2021-07-01)